Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      U.S. Recruitment for Ohio State University Study Evaluating EmeTerm in Adults With Chronic Nausea and Vomiting


      News provided by

      WAT Medical Enterprise Ltd.

      Aug 17, 2026, 09:00 ET

      Share this article

      Share this article


      VANCOUVER, BC, Aug. 17, 2026 /PRNewswire/ -- Participant recruitment information for a clinical study being conducted at The Ohio State University has been publicly posted on ClinicalTrials.gov. The study, titled "Evaluating the Effect of Wearing a TENS Device in Nausea Relief," is also known as the WINNER Study. It is registered under ClinicalTrials.gov identifier NCT07720323 and is currently listed as recruiting. The study is sponsored by The Ohio State University and is expected to enroll approximately 120 adults.

      Continue Reading
      WAT Medical Enterprise Ltd.
      WAT Medical Enterprise Ltd.

      ClinicalTrials.gov is a public registry and results database for clinical research studies. It was developed and is supported by the U.S. National Library of Medicine, part of the National Institutes of Health, to make information about ongoing and completed clinical studies accessible to patients, healthcare professionals and researchers.

      Understanding Cyclic Vomiting Syndrome and Chronic Nausea

      Cyclic vomiting syndrome, commonly known as CVS, is a disorder characterized by sudden and repeated episodes of severe nausea and vomiting. Episodes may last from several hours to several days and are typically separated by longer periods during which the person experiences few or no symptoms. The recurring and unpredictable nature of CVS can significantly disrupt work, education, daily activities and overall quality of life.

      CVS is one condition within the broader spectrum of disorders involving recurrent or persistent nausea and vomiting. Some patients may experience chronic nausea between vomiting episodes, while others may have persistent nausea associated with abdominal pain, bloating, constipation, reduced appetite, fatigue, sleep disturbance or other gastrointestinal symptoms.

      About the WINNER Study

      The WINNER (WearINg a TENS-device in Nausea Relief) Study is a single-center clinical trial conducted at The Ohio State University to evaluate the effectiveness of the EmeTerm wearable TENS device in adults with nausea that has persisted for more than 2 months.

      EmeTerm is a wearable transcutaneous electrical nerve stimulation device, worn around the wrist and delivers controlled electrical stimulation to the median nerve. The study will examine whether using the device reduces the average weekly frequency of moderate-to-severe nausea compared with symptoms recorded before device use. Researchers will also assess changes in vomiting frequency, nausea duration, use of anti-nausea medication and other aspects of gastrointestinal health and general wellbeing.

      The study is a single-group trial without a placebo arm. Each participant will serve as their own comparison, with symptoms during the 12-week device-use period compared with symptoms documented during the preceding two-week baseline period.

      The primary outcome is the change in the average weekly number of days on which participants experience moderate or severe nausea. Secondary outcomes include changes in vomiting frequency and the use of anti-nausea medications. The study will also explore possible changes in abdominal pain, bloating, constipation, appetite, sleep, mood, stress, fatigue, quality of life and hope.

      Who May Be Eligible to Participate

      According to the ClinicalTrials.gov recruitment listing, potential participants must meet the following principal requirements:

      • Be 18 years of age or older;
      • Have experienced nausea for more than two months;
      • Be able to understand English;
      • Be receiving care at The Ohio State University; and
      • Be able to complete electronic questionnaires using a smartphone or computer.

      The study does not accept healthy volunteers. Final eligibility will be determined by the study team following screening.

      Invitation to Potential Participants

      Adults experiencing persistent nausea, recurrent vomiting or related gastrointestinal symptoms who currently receive care at The Ohio State University may review the official study information and speak with their healthcare provider about whether participation may be appropriate.

      Individuals who believe they may meet the eligibility requirements can search for NCT07720323 on ClinicalTrials.gov to review the full study description, current recruitment status, study location and official contact information. For additional information about the study, interested individuals may contact the study team directly at [email protected].

      About WAT Medical and EmeTerm

      WAT Medical Enterprise Ltd. is a medical technology company specializing in wearable neuromodulation technologies, with more than 10 years of research and development experience focused on targeted nerve stimulation. The company develops non-invasive wearable technologies designed to support symptom management across areas including nausea, motion sickness and migraine.

      EmeTerm is WAT Medical's wearable anti-nausea device based on Transcutaneous Electrical Acupoint Stimulation (TEAS) technology. Designed to deliver controlled electrical stimulation at the wrist, EmeTerm is FDA cleared and provides a non-pharmacological approach to nausea and vomiting relief.

      EmeTerm is supported by clinical research and independent peer-reviewed studies, including research published in JAMA Surgery and the British Journal of Anaesthesia (BJA). EmeTerm has also achieved strong consumer recognition, ranking as the No. 1 best-selling medical-grade wearable anti-nausea device on Amazon and receiving consistently positive reviews from users. WAT Medical continues to advance targeted neuromodulation technologies through ongoing research and clinical collaboration.

      References

      1. https://clinicaltrials.gov/study/NCT07720323?term=EMETERM&rank=1
      2. Zheng D, Ding P, Gong M, et al. (2026). Transcutaneous Electrical Acupoint Stimulation vs Metoclopramide for Moderate to Severe Postoperative Nausea and Vomiting: A Randomized Clinical Trial. JAMA Surg. doi:10.1001/jamasurg.2025.6394
      3. Wang, N., et al. (2022). Wearable transcutaneous electrical acupoint stimulation bracelet for prevention of postoperative nausea and vomiting in patients undergoing hysteroscopic surgery: a randomised controlled trial. British Journal of Anaesthesia, 129(4), e85-e87.
      4. www.emeterm.com
      5. www.watmedical.com

      SOURCE WAT Medical Enterprise Ltd.

      Modal title

      Also from this source

      WAT Medical Marks Its 8th Consecutive Year of Charitable Giving, Expanding Support for the Veteran Community

      WAT Medical Marks Its 8th Consecutive Year of Charitable Giving, Expanding Support for the Veteran Community

      WAT Medical Enterprise Ltd. proudly announces its eighth consecutive year of charitable giving. This year, the company continues its annual financial ...

      WAT Medical Secures MOHAP Manufacturing Site Registration in the UAE

      WAT Medical Secures MOHAP Manufacturing Site Registration in the UAE

      WAT Medical proudly announces that it has successfully obtained a Manufacturing Site Registration Certificate issued by the UAE Ministry of Health &...

      More Releases From This Source

      Explore

      Medical Equipment

      Medical Equipment

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.